Remibrutinib (1) – Rhapsido®
Chronic spontaneous urticaria
Characteristics
| Start date | 01.06.2026 |
|---|---|
| Resolution | 19.11.2026 – active procedure |
| INN | Remibrutinib |
| Brand name | Rhapsido® |
| Pharm. company | Novartis Pharma GmbH |
| G-BA Procedure ID | D-1336 |
| Therapeutic area | Skin diseases |
| Reason for procedure | Initial assessment |
Associated procedures
<< List of all resolutions